Nakajima N, Mizoe N, Misawa F, et al. - In patients with schizophrenia who had been taking long-acting injectable second-generation antipsychotics (LAI-SGAs) for at least 1 year, researchers conducted this retrospective cohort study to investigate longitudinal changes in antipsychotic dose over a 3-year period. At 12, 24 and 36 months, the total daily chlorpromazine equivalent dose of antipsychotics was evaluated in comparison with the baseline dose at 3 months after the start of LAI-SGAs. The inclusion criteria were met by a total of 154 patients. Changes in total daily dose were significantly negatively correlated with age and total antipsychotic dose at 3 months. In patients treated with LAI-SGAs in the maintenance period, the antipsychotic dose remained essentially unchanged during long-term care, although there was a rise in some patients. Total patients. Total daily dose was increased in 43 (27.9%), 31 (34.8%) and 22 patients (36.7%) at 12, 24 and 36 months, respectively.